Last reviewed · How we verify
Hyaluronic acid 0.05% & Ectoine 2.0%
Hyaluronic acid and ectoine work together to hydrate and protect the ocular surface by retaining moisture and stabilizing cell membranes against osmotic stress.
Hyaluronic acid and ectoine work together to hydrate and protect the ocular surface by retaining moisture and stabilizing cell membranes against osmotic stress. Used for Dry eye disease / Keratoconjunctivitis sicca, Ocular surface protection and lubrication.
At a glance
| Generic name | Hyaluronic acid 0.05% & Ectoine 2.0% |
|---|---|
| Also known as | Hylo-Dual |
| Sponsor | Michael Marchand, MD |
| Drug class | Ophthalmic lubricant and protectant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Hyaluronic acid is a natural humectant that binds water and lubricates the cornea and conjunctiva, reducing friction and improving tear film stability. Ectoine is an organic osmolyte that protects cells from dehydration and osmotic stress by stabilizing proteins and cell membranes, enhancing the eye's natural defense mechanisms against dry conditions.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
- Ocular surface protection and lubrication
Common side effects
- Mild ocular irritation
- Transient blurred vision
- Foreign body sensation
Key clinical trials
- Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyaluronic acid 0.05% & Ectoine 2.0% CI brief — competitive landscape report
- Hyaluronic acid 0.05% & Ectoine 2.0% updates RSS · CI watch RSS
- Michael Marchand, MD portfolio CI